Literature DB >> 19595803

Comparison of aspiration-sclerotherapy with hydrocelectomy in the management of hydrocele: a prospective randomized study.

Sudeep Khaniya1, Chandra Shekhar Agrawal, Rabin Koirala, Rajendra Regmi, Shailesh Adhikary.   

Abstract

BACKGROUND: Hydrocelectomy is practiced as the gold standard technique for the treatment of hydrocele worldwide. Aspiration and sclerotherapy is cheap, less invasive and safe compared to hydrocelectomy. However, the outcomes are inconsistent because of lack of uniformity in methods and sclerosing agents used.
MATERIALS AND METHODS: This was a randomized controlled study conducted in a university hospital for a period of one year. Sixty symptomatic adult males without fertility concern or coexisting scrotal pathology were enrolled. Aspiration and sclerotherapy and hydrocelectomy were performed in 30 each. PRIMARY OUTCOME MEASURES: incidence of complications, loss of working days, cost involved, recurrence rate and patient's satisfaction. Patients were followed up till 6 months after the procedures.
RESULTS: Eight patients (26.7%) after hydrocelectomy developed fever which was significantly more (p<0.05) than 2 patients (6.7%) following sclerotherapy. Four patients (14%) with hydrocelectomy had infection (p<0.05). The incidence of pain and haematocele between the two groups were comparable. Nine patients (34.6%) after sclerotherapy developed recurrence at 3 months. All patients developed recurrence after repeat aspiration and sclerotherapy. The level of satisfaction was more in hydrocelectomy 19 (95%) versus 13 (61.9%) patients in sclerotherapy (p<0.05). The cost involved was fivefold and the loss of working days sevenfold in hydrocelectomy (p<0.01) as compared to sclerotherapy.
CONCLUSION: Although aspiration and sclerotherapy had less complications, morbidity and was cheaper, it had lower success rate and less patient's satisfaction than hydrocelectomy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19595803     DOI: 10.1016/j.ijsu.2009.07.002

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  9 in total

Review 1.  Management of hydrocele in adolescent patients.

Authors:  Marcello Cimador; Marco Castagnetti; Enrico De Grazia
Journal:  Nat Rev Urol       Date:  2010-06-15       Impact factor: 14.432

2.  Jaboulay's technique contrasted with a novel hydrocelectomy technique using a vessel sealer in the treatment of adult hydrocele: a prospective randomized study.

Authors:  Fatih Ozkaya; Ozer Ural Cakici
Journal:  Int Urol Nephrol       Date:  2019-11-27       Impact factor: 2.370

3.  Evaluation of the Role of Sodium Tetradecyl Sulfate as a Sclerosant in the Treatment of Primary Hydrocele.

Authors:  Osman Musa; Arijit Roy; Nisar Ahmad Ansari; Jagadamba Sharan
Journal:  Indian J Surg       Date:  2013-02-09       Impact factor: 0.656

4.  Techniques - Mini-incision and plication (MIP) cure hydrocele: A minimally invasive surgical variation.

Authors:  Anthony Joe Nassour; Darius Ashrafi; Dinesh Patel
Journal:  Can Urol Assoc J       Date:  2022-05       Impact factor: 1.862

5.  The Application of Scrotoscope-Assisted Minimally Invasive Excision for Epididymal Mass: An Initial Report.

Authors:  Chuying Qin; Jinrui Yang; Ruochen Zhang; Yaojin Yang; Wanghai Cai; Tao Li; Qingguo Zhu; Liefu Ye; Yunliang Gao; Yongbao Wei
Journal:  Front Surg       Date:  2022-02-24

6.  Comparison of outcomes and costs of surgery versus sclerotherapy to treat hydrocele.

Authors:  Fernando Korkes; Saulo Borborema Teles; Matheus Prado Nascimento; Samira Scalso de Almeida; Artur Martins Codeço
Journal:  Einstein (Sao Paulo)       Date:  2021-07-16

7.  A case of Fournier's gangrene after hydrocelectomy.

Authors:  Badereddin Mohamad Al-Ali; Helmut Popper; Karl Pummer
Journal:  Cent European J Urol       Date:  2012-06-12

8.  Recurrent hydrocoele.

Authors:  Kelly Parks; Lawrence Leung
Journal:  J Family Med Prim Care       Date:  2013-01

9.  Minimally access versus conventional hydrocelectomy: a randomized trial.

Authors:  Aly Saber
Journal:  Int Braz J Urol       Date:  2015 Jul-Aug       Impact factor: 1.541

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.